Contact us for free information or to start a free case review.
A Food and Drug Administration advisory panel is recommending restrictions on the use of anemia drugs for cancer patients.
The panel recommendation comes in response to growing safety concerns over the risks associated with the anemia drugs Aranesp and Procrit, which are used to counter chemotherapy-induced anemia in cancer patients.
Safety Concerns& Recommendations
Both drugs have been linked to rapid tumor growth and shortened survival in certain patient populations. In a 9 to 5 vote, the panel recommended that Aranesp and Procrit not be used in patients with breast cancer or cancer of the head and neck.
The panel also voted to have patients sign consent forms before taking the drugs. The FDA is not required to heed panel recommendations, though it usually does.
Procrit and Amgen are top selling drugs, bringing in billions of dollars in sales for Johnson & Johnson and Amgen, respectively.
(Source: The New York Times)
Injured by a defective drug? Contact an experienced attorney near you today to discuss your legal options.
Copyright © 2001 - 2012 Online Lawyer Source
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.